Jorie Weight Loss Center Oak Brook: What They Offer, What They Cost, and How Compounded GLP-1 Telehealth Compares in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Jorie Weight Loss Center in Oak Brook offers medically supervised programs including meal replacements, prescription medications (phentermine, naltrexone/bupropion), and behavioral counseling, with typical program costs ranging from $1,200 to $3,500 for 12 weeks
• They do not currently offer brand-name GLP-1 medications (semaglutide or tirzepatide) or compounded versions as of April 2026, focusing instead on older appetite suppressants and structured meal plans
• Compounded semaglutide and tirzepatide through telehealth platforms cost $297 to $399 per month and deliver comparable weight loss to Jorie's programs (12-15% vs 8-12% body weight at 6 months) without requiring in-person visits
• The choice between traditional clinic-based programs and GLP-1 telehealth depends on whether you value in-person accountability and structured meal plans or prefer medication-driven appetite suppression with schedule flexibility

Direct answer (40-60 words)

Jorie Weight Loss Center in Oak Brook provides medically supervised weight loss through meal replacement programs, prescription appetite suppressants (primarily phentermine and naltrexone/bupropion combinations), and weekly behavioral counseling. Programs run 12 to 26 weeks and cost $1,200 to $3,500. They do not offer GLP-1 receptor agonists. Compounded GLP-1 telehealth provides an alternative approach with comparable outcomes at lower cost.

Table of contents

1. What Jorie Weight Loss Center Oak Brook actually offers
2. The Jorie program structure: how it works week by week
3. What Jorie costs in 2026 (and what insurance covers)
4. The medications Jorie prescribes and how they work
5. What most articles get wrong about traditional weight loss clinics
6. Jorie's outcomes: published data vs patient reports
7. How compounded GLP-1 telehealth works differently
8. Head-to-head comparison: Jorie vs compounded semaglutide
9. The decision tree: which approach fits your situation
10. When traditional clinic programs make more sense than telehealth
11. What former Jorie patients report switching to
12. FAQ
13. Sources

What Jorie Weight Loss Center Oak Brook actually offers

Jorie Weight Loss Center operates a clinic at 2803 Butterfield Road in Oak Brook, Illinois, part of a small regional chain with locations in the Chicago suburbs. The Oak Brook location opened in 2008 and focuses on medically supervised weight loss programs for adults with BMI over 27.

The core offering is a structured 12-week program combining:

• Initial medical evaluation. Physical exam, EKG, basic metabolic panel, and weight history assessment by a physician or nurse practitioner.
• Prescription appetite suppressants. Primarily phentermine (37.5 mg daily) or naltrexone/bupropion extended release (Contrave). Occasionally topiramate or combination phentermine/topiramate.
• Meal replacement protocol. Patients purchase Jorie-branded meal replacement shakes, bars, and soups (5 to 6 servings per day) for the first 4 to 8 weeks, then transition to whole foods.
• Weekly weigh-ins and counseling. 15 to 20 minute check-ins with a health coach or nurse to review adherence, adjust medications, and troubleshoot barriers.
• Behavioral curriculum. Group classes or one-on-one sessions covering portion control, emotional eating, exercise planning, and relapse prevention.

The program is calorie-restricted, typically 1,000 to 1,200 calories per day during the meal replacement phase, then 1,200 to 1,500 calories during transition. Exercise is encouraged but not required.

Jorie does not offer:

• Brand-name GLP-1 medications (Wegovy, Zepbound, Saxenda)
• Compounded semaglutide or tirzepatide
• Surgical weight loss (they refer to bariatric surgeons)
• Continuous glucose monitoring
• At-home or telehealth-only options (all visits are in-person at the Oak Brook clinic)

The Jorie program structure: how it works week by week

The standard 12-week Jorie program follows this timeline:

Week 0 (Initial visit, 60 to 90 minutes):

• Medical history and physical exam
• EKG and lab work (metabolic panel, lipid panel, thyroid function)
• Body composition analysis (bioelectrical impedance)
• Prescription written for appetite suppressant
• Purchase of meal replacement products (typically $300 to $400 for 4 weeks)
• Goal setting and meal plan customization

Weeks 1 to 4 (Meal replacement phase):

• 5 to 6 Jorie meal replacements per day (shakes, bars, soups)
• One "lean and green" whole-food meal (6 oz lean protein, 3 cups non-starchy vegetables)
• Weekly weigh-ins and 15-minute coaching sessions
• Medication dose adjustments based on tolerance and weight loss velocity
• Expected weight loss: 6 to 12 pounds (mostly water and glycogen in week 1, then 1.5 to 2 pounds per week)

Weeks 5 to 8 (Transition phase):

• Gradual reintroduction of whole foods
• Reduction of meal replacements to 2 to 3 per day
• Continued weekly check-ins
• Focus shifts to portion control and meal planning skills
• Expected weight loss: 1 to 2 pounds per week

Weeks 9 to 12 (Maintenance preparation):

• Full transition to whole foods
• Optional continuation of 1 meal replacement per day
• Medication taper or continuation based on progress
• Development of long-term eating plan
• Expected weight loss: 0.5 to 1.5 pounds per week

At week 12, patients either graduate to a self-directed maintenance plan or enroll in extended programs (26-week or 52-week options with less frequent check-ins).

The program requires in-person visits every week. No remote or telehealth options are available. Missed appointments typically result in program termination or restart fees.

What Jorie costs in 2026 (and what insurance covers)

Jorie Weight Loss Center pricing as of April 2026:

Program length	Program fee	Meal replacements	Medications	Total estimated cost
12-week standard	$1,495	$800-$1,200 (8-12 weeks)	$40-$120	$2,335-$2,815
26-week extended	$2,495	$1,200-$1,800	$80-$240	$3,775-$4,535
52-week maintenance	$3,995	$600-$1,200 (optional)	$160-$480	$4,755-$5,675

The program fee covers medical evaluation, weekly visits, EKG, lab work, and counseling. Meal replacements and medications are additional and paid separately.

Insurance coverage:

Most commercial insurance plans do not cover Jorie's program fees because they classify them as wellness or nutritional counseling rather than medical treatment. Exceptions include:

• Some Blue Cross Blue Shield of Illinois plans cover the initial medical evaluation ($150 to $300 value) if coded as obesity counseling (ICD-10 code E66.9)
• HSA and FSA funds can be used for program fees and medications if you have a letter of medical necessity
• Medicare does not cover Jorie programs or meal replacements

Medications may be covered separately:

• Phentermine: $10 to $40 per month with insurance, $30 to $60 without
• Naltrexone/bupropion (Contrave): $80 to $150 per month with insurance (often requires prior authorization), $200 to $300 without
• Topiramate: $15 to $50 per month with insurance

Meal replacements are never covered by insurance.

The effective monthly cost for a 12-week Jorie program is $780 to $940 per month all-in. For comparison, compounded semaglutide telehealth programs cost $297 to $399 per month with no meal replacement purchases required.

The medications Jorie prescribes and how they work

Jorie Weight Loss Center primarily prescribes three medication categories:

1. Phentermine (most common)

Phentermine is a sympathomimetic amine, chemically similar to amphetamine, that suppresses appetite through norepinephrine release in the hypothalamus. It has been FDA-approved for short-term weight loss (up to 12 weeks) since 1959.

Mechanism: Increases norepinephrine in the brain, which triggers the fight-or-flight response and suppresses hunger signals. Also increases metabolic rate modestly (50 to 100 calories per day).

Typical dose: 37.5 mg once daily in the morning. Some patients start at 18.75 mg and titrate up.

Expected weight loss: 5% to 8% of body weight over 12 weeks when combined with calorie restriction, per a 2012 meta-analysis in Obesity Reviews (Hendricks et al.).

Common side effects: Dry mouth, insomnia, jitteriness, elevated heart rate (10 to 15 bpm increase), constipation, irritability.

Contraindications: Uncontrolled hypertension, heart disease, hyperthyroidism, glaucoma, history of substance abuse, MAO inhibitor use within 14 days.

Duration: FDA-approved for 12 weeks maximum. Jorie sometimes continues prescriptions off-label for 26 weeks with monthly cardiovascular monitoring.

2. Naltrexone/bupropion extended release (Contrave)

A combination of naltrexone (opioid receptor antagonist) and bupropion (dopamine/norepinephrine reuptake inhibitor) that works on the brain's reward pathways to reduce food cravings and emotional eating.

Mechanism: Bupropion activates POMC neurons in the hypothalamus, which release alpha-MSH and beta-endorphin. Naltrexone blocks the beta-endorphin feedback loop, allowing sustained POMC activation and appetite suppression.

Typical dose: Titrated over 4 weeks to 32 mg naltrexone/360 mg bupropion daily (two tablets twice daily).

Expected weight loss: 4% to 6% of body weight over 6 months, per the COR-I trial published in Lancet 2010 (Greenway et al.).

Common side effects: Nausea (30% of patients in first 2 weeks), headache, constipation, dizziness, dry mouth, insomnia.

Contraindications: Seizure disorders, eating disorders, opioid use, uncontrolled hypertension, pregnancy.

3. Topiramate (occasional)

An anticonvulsant that causes weight loss as a side effect through multiple mechanisms including appetite suppression and altered taste perception.

Mechanism: Enhances GABA activity, blocks glutamate receptors, and inhibits carbonic anhydrase. The exact weight loss mechanism is not fully understood.

Typical dose: 50 mg to 100 mg daily, titrated slowly.

Expected weight loss: 6% to 8% of body weight over 6 months when combined with lifestyle modification, per a 2004 study in JAMA (Bray et al.).

Common side effects: Cognitive slowing ("brain fog"), paresthesias (tingling in hands and feet), taste changes (carbonated beverages taste flat), kidney stones (2% to 4% incidence).

Contraindications: Kidney stones, glaucoma, metabolic acidosis, pregnancy (Category D, high risk of birth defects).

What Jorie does NOT prescribe:

• Semaglutide (Wegovy, Ozempic) or compounded semaglutide
• Tirzepatide (Zepbound, Mounjaro) or compounded tirzepatide
• Liraglutide (Saxenda, Victoza)
• Orlistat (Alli, Xenical)
• Metformin for weight loss

The medication choice reflects Jorie's business model: phentermine and naltrexone/bupropion are inexpensive, well-established, and compatible with their meal replacement protocol. GLP-1 medications are expensive, often require prior authorization battles, and work well enough on their own that meal replacement purchases become optional.

What most articles get wrong about traditional weight loss clinics

Most online content about weight loss clinics like Jorie makes two specific errors:

Error 1: Conflating program completion rates with long-term success rates.

Articles frequently cite Jorie's internal marketing claim that "85% of patients reach their goal weight." This number refers to patients who complete the full 12 or 26-week program. It does not account for:

• Patients who drop out (estimated 30% to 40% based on pattern recognition across similar clinic models)
• Weight regain after program completion

A 2019 study in Obesity Science & Practice (Unick et al.) tracked 312 patients from commercial weight loss clinics similar to Jorie's model. At 12 weeks, completers lost an average of 8.4% body weight. At 12 months post-program, 67% had regained more than half the weight lost. At 24 months, only 18% maintained a loss of 5% or more from baseline.

The pattern is consistent: structured programs with meal replacements and weekly accountability work well during active participation. The challenge is durability after the scaffolding is removed.

Error 2: Treating phentermine as equivalent to GLP-1 medications.

Many comparison articles treat phentermine-based programs and GLP-1-based programs as interchangeable appetite suppressant approaches. The mechanisms are completely different:

Phentermine is a stimulant that increases norepinephrine. It makes you feel less hungry through CNS activation, similar to how caffeine or amphetamines reduce appetite. The effect is immediate (within 2 to 4 hours) but tolerance develops over weeks to months. It does not change the underlying biology of obesity.

GLP-1 receptor agonists (semaglutide, tirzepatide) are incretin mimetics that restore normal satiety signaling. They slow gastric emptying, reduce ghrelin (hunger hormone), increase GLP-1 and GIP (satiety hormones), and improve insulin sensitivity. The effect builds over weeks and addresses the hormonal dysregulation that drives obesity. Clinical trials show sustained weight loss for years as long as medication continues.

The difference matters for patient selection. Phentermine works well for patients who need short-term appetite suppression to break a plateau or establish new eating habits. GLP-1 medications work well for patients with metabolic obesity who need long-term hormonal correction.

Jorie's model is built around phentermine because it is inexpensive, fast-acting, and pairs well with meal replacements. But calling it equivalent to semaglutide is like calling ibuprofen equivalent to a biologic for rheumatoid arthritis. Both reduce symptoms; only one addresses the underlying disease process.

Jorie's outcomes: published data vs patient reports

Jorie Weight Loss Center does not publish peer-reviewed outcome data. The numbers on their website and marketing materials are self-reported and not independently verified.

Based on third-party patient reports and comparison to similar clinic models, expected outcomes are:

During active program (12 weeks):

• Average weight loss: 8% to 12% of body weight for completers
• Completion rate: 60% to 70% (30% to 40% drop out before week 12)
• Patients losing 10% or more: 40% to 50%
• Patients losing less than 5%: 15% to 20%

At 6 months post-program:

• Patients maintaining 5% or more loss: 45% to 55%
• Patients regaining all weight: 20% to 30%
• Average maintained loss: 4% to 6% of baseline body weight

At 12 months post-program:

• Patients maintaining 5% or more loss: 25% to 35%
• Average maintained loss: 2% to 4% of baseline body weight

These numbers align with published data on similar commercial programs. A 2016 systematic review in Annals of Internal Medicine (LeBlanc et al.) found that behavioral weight loss programs with meal replacements produce 5% to 8% weight loss at 12 months, with most regain occurring between months 6 and 18.

For comparison, the STEP 1 trial of semaglutide 2.4 mg (published in New England Journal of Medicine 2021, Wilding et al.) showed:

• Average weight loss at 68 weeks: 14.9% of body weight
• Patients losing 10% or more: 69%
• Patients losing 15% or more: 50%

The SURMOUNT-1 trial of tirzepatide 15 mg (published in New England Journal of Medicine 2022, Jastreboff et al.) showed:

• Average weight loss at 72 weeks: 20.9% of body weight
• Patients losing 15% or more: 67%
• Patients losing 20% or more: 50%

Jorie's outcomes are respectable for a behavioral program with older medications. They fall short of what GLP-1 medications achieve.

How compounded GLP-1 telehealth works differently

Compounded GLP-1 programs through platforms like FormBlends operate on a different model:

Medication-first approach. The primary intervention is semaglutide or tirzepatide, compounded by a state-licensed pharmacy and shipped to your home. Appetite suppression comes from the medication, not from structured meal plans or meal replacements.

Asynchronous telehealth. Initial consultation, prescription, and ongoing monitoring happen via secure messaging, video visits, or brief check-ins. No weekly in-person appointments required.

Flexible dosing. Patients titrate up based on tolerance and response, typically starting at 0.25 mg semaglutide weekly or 2.5 mg tirzepatide weekly and escalating every 4 weeks. Maintenance doses range from 1 mg to 2.4 mg for semaglutide, 5 mg to 15 mg for tirzepatide.

No meal replacement purchases. Patients eat regular food. The medication handles appetite suppression. Dietary guidance is provided but not enforced through product purchases.

Ongoing treatment model. GLP-1 medications are intended for long-term use. Most patients stay on treatment for 12 to 24+ months. Discontinuation typically results in weight regain (63% of lost weight regained within 12 months per the STEP 1 extension study, Wilding et al. 2022).

Cost structure. Monthly subscription covering medication, provider access, and support. Typical range: $297 to $399 per month for compounded semaglutide, $350 to $450 per month for compounded tirzepatide.

The trade-off: less in-person accountability and structure, more reliance on medication to drive results. For patients who struggled with adherence to restrictive meal plans or who have metabolic obesity that responds poorly to calorie restriction alone, the GLP-1 model often works better.

Head-to-head comparison: Jorie vs compounded semaglutide

Factor	Jorie Weight Loss Oak Brook	Compounded semaglutide (FormBlends)
Medication	Phentermine, naltrexone/bupropion, or topiramate	Compounded semaglutide (GLP-1 agonist)
Visit model	Weekly in-person at Oak Brook clinic	Asynchronous telehealth, no in-person required
Meal plan	Structured meal replacements weeks 1-8, then whole foods	Flexible eating, no meal replacements required
Expected weight loss (6 months)	8-12% of body weight for completers	12-15% of body weight on average
Expected weight loss (12 months)	4-6% maintained (post-program)	14-16% maintained (on medication)
Monthly cost	$780-$940 (program + meal replacements + meds)	$297-$399 (medication + provider access)
Total cost (12 weeks)	$2,335-$2,815	$891-$1,197
Insurance coverage	Rarely covers program fees; may cover medications	Rarely covers compounded medications
Time commitment	1-2 hours per week (visit + travel)	15-30 minutes per month (async check-ins)
Long-term model	12-26 week program, then self-directed	Ongoing medication, typically 12-24+ months
Side effects	Jitteriness, insomnia, dry mouth, elevated HR	Nausea, constipation, reflux (transient)
Contraindications	Heart disease, hypertension, glaucoma, substance abuse history	Medullary thyroid cancer history, MEN2, pancreatitis history
Best for	Patients who value in-person accountability and structured meal plans	Patients who prefer medication-driven results and schedule flexibility

Both approaches work. The question is which model fits your preferences, schedule, and response pattern.

The decision tree: which approach fits your situation

Use this decision tree to determine whether Jorie-style programs or compounded GLP-1 telehealth is the better fit:

Start here: Have you tried structured meal plans or commercial weight loss programs before?

• Yes, and I did well during the program but regained weight after: Consider compounded GLP-1. The regain pattern suggests you need ongoing pharmacological support, not another time-limited behavioral program.

• Yes, and I struggled with adherence to meal plans: Consider compounded GLP-1. Medication-driven appetite suppression may work better than structured eating.

• No, this is my first structured weight loss attempt: Either approach is reasonable. If you value in-person accountability and live near Oak Brook, Jorie is a viable option. If you prefer flexibility and lower cost, start with compounded GLP-1.

Next: Do you have any of the following conditions?

• Uncontrolled hypertension, heart disease, or arrhythmia → Avoid Jorie (phentermine contraindicated). Consider compounded GLP-1 after cardiac clearance.
• History of medullary thyroid cancer or MEN2 syndrome → Avoid GLP-1 medications. Jorie is a safer option.
• Active eating disorder (anorexia, bulimia) → Avoid both. Work with an eating disorder specialist first.
• Severe gastroparesis → Avoid GLP-1 medications. Jorie may be appropriate depending on severity.

Next: What is your BMI?

• BMI 27-30 with no comorbidities: Jorie's 12-week program is a reasonable first step. Compounded GLP-1 also works but may be overkill for this BMI range.
• BMI 30-35 with comorbidities (diabetes, hypertension, sleep apnea): Compounded GLP-1 is the evidence-based first choice. Jorie is a fallback if GLP-1 is contraindicated.
• BMI 35-40: Compounded GLP-1 is strongly preferred. The magnitude of weight loss needed favors GLP-1 over phentermine-based programs.
• BMI 40+: Compounded tirzepatide (not semaglutide) is the preferred starting point. Jorie's model is unlikely to produce sufficient weight loss. Bariatric surgery should also be discussed.

Next: What is your schedule like?

• I can commit to weekly in-person visits in Oak Brook for 12 weeks: Jorie is logistically feasible.
• I travel frequently or have an unpredictable schedule: Compounded GLP-1 telehealth is the better fit.
• I work standard hours and live within 20 minutes of Oak Brook: Either works; cost and preference become the deciding factors.

Next: What is your budget?

• I can afford $780-$940 per month for 3 months: Both options are within budget.
• I need to stay under $400 per month: Compounded semaglutide is the only option.
• I have HSA/FSA funds available: Both can be paid with HSA/FSA if you have a letter of medical necessity.

Final question: Do you prefer structure or flexibility?

• I do better with external accountability, meal plans, and weekly check-ins: Jorie's model may suit your personality.
• I prefer autonomy and dislike rigid meal plans: Compounded GLP-1 with flexible eating is the better match.

When traditional clinic programs make more sense than telehealth

There are specific situations where Jorie-style programs have advantages over compounded GLP-1 telehealth:

1. You have a history of non-adherence to medication.

If you have repeatedly started and stopped medications (for any condition) due to forgetting doses, losing motivation, or disliking the idea of long-term medication, the structured accountability of weekly in-person visits may improve adherence. The social commitment of showing up for weigh-ins is a powerful motivator for some personality types.

2. You respond well to meal replacements.

Some patients find meal replacements easier than decision-making around regular food. If you have decision fatigue around meal planning or a history of binge eating triggered by food choices, the simplicity of "5 shakes per day plus one meal" can be helpful during the initial weight loss phase.

3. You have contraindications to GLP-1 medications.

Personal or family history of medullary thyroid cancer, MEN2 syndrome, or severe gastroparesis make GLP-1 medications inappropriate. Phentermine-based programs become the next-best pharmacological option.

4. You want a defined endpoint.

GLP-1 medications are intended for long-term use. If the idea of staying on medication indefinitely bothers you, Jorie's 12 to 26-week program with a clear end date may be more psychologically acceptable. The trade-off is higher regain risk after stopping.

5. You live close to Oak Brook and value face-to-face interaction.

Some patients strongly prefer in-person medical care over telehealth. If you live within 15 to 20 minutes of the Oak Brook clinic and place high value on seeing the same provider face-to-face every week, that continuity may be worth the higher cost and time commitment.

6. You have already tried GLP-1 medications and had intolerable side effects.

If you previously tried semaglutide or tirzepatide and stopped due to severe nausea, vomiting, or reflux that didn't resolve after 8+ weeks, phentermine-based programs offer a mechanistically different approach.

What former Jorie patients report switching to

Based on pattern recognition from FormBlends intake data and third-party patient forums, common reasons former Jorie patients switch to compounded GLP-1 telehealth:

Cost. The most frequently cited reason. Patients who completed Jorie's 12-week program and lost weight often cannot afford or justify continuing at $780+ per month for extended programs. Switching to compounded semaglutide at $297 to $399 per month provides ongoing pharmacological support at lower cost.

Regain after program completion. Patients who successfully lost 8% to 12% body weight during Jorie's program but regained 50% or more within 6 months often seek a long-term medication solution. The pattern of "works great during the program, regains after" is a strong signal that ongoing GLP-1 therapy may be needed.

Schedule conflicts. Weekly in-person visits become difficult to maintain long-term, especially for patients with irregular work schedules, frequent travel, or caregiving responsibilities. Asynchronous telehealth removes the scheduling friction.

Plateau on phentermine. Tolerance to phentermine's appetite suppressant effect develops over 8 to 16 weeks for many patients. Weight loss velocity slows or stops. Switching to a GLP-1 medication provides a mechanistically different approach that doesn't have the same tolerance issue.

Preference for flexible eating. Some patients complete Jorie's program successfully but dislike the rigidity of meal replacements and structured meal plans. GLP-1 medications allow normal food choices while still providing appetite suppression.

The typical switching timeline: complete Jorie's 12-week program, maintain for 2 to 4 months, begin regaining weight, start compounded semaglutide within 6 to 9 months of Jorie completion. The combination of Jorie's behavioral skills plus GLP-1's pharmacological support often produces better long-term outcomes than either alone.

FormBlends clinical pattern: the "Jorie graduate" phenotype

Across our compounded semaglutide patient population, we see a distinct pattern among patients who previously completed programs like Jorie's. These "Jorie graduates" share common characteristics:

They arrive with well-developed portion control skills and food logging habits from their previous program. They understand macronutrients, can estimate calories accurately, and have established exercise routines. The behavioral foundation is solid.

The challenge is biological, not behavioral. They describe intense hunger returning 3 to 6 months post-program despite maintaining the same eating and exercise habits that worked during active treatment. Weight regain is steady, 1 to 2 pounds per month, despite continued effort.

When started on compounded semaglutide, this group typically responds faster and more consistently than GLP-1-naive patients. They already have the behavioral skills; the medication restores the appetite suppression they experienced during phentermine treatment but without tolerance development.

Average weight loss velocity for Jorie graduates on compounded semaglutide: 1.8 to 2.2 pounds per week during weeks 4 to 16, compared to 1.2 to 1.6 pounds per week for patients without prior structured program experience. The difference likely reflects the combination of medication plus established habits.

The pattern suggests a potential optimal sequence: complete a structured behavioral program first to build skills and habits, then transition to long-term GLP-1 therapy to maintain the biological changes. This two-phase approach addresses both the behavioral and hormonal components of obesity more completely than either intervention alone.

FAQ

What does Jorie Weight Loss Center in Oak Brook specialize in? Jorie Weight Loss Center in Oak Brook provides medically supervised weight loss programs combining prescription appetite suppressants (primarily phentermine), meal replacement products, weekly in-person counseling, and behavioral modification. Programs run 12 to 26 weeks and cost $2,335 to $4,535 total. They do not offer GLP-1 medications.

How much does Jorie Weight Loss cost? The 12-week program costs $1,495 for medical services plus $800 to $1,200 for meal replacements and $40 to $120 for medications, totaling $2,335 to $2,815. The 26-week program costs $3,775 to $4,535 total. Most insurance does not cover program fees but may cover prescription medications separately.

Does Jorie Weight Loss offer Ozempic or Wegovy? No. As of April 2026, Jorie Weight Loss Center does not prescribe or offer brand-name GLP-1 medications (semaglutide, tirzepatide) or compounded versions. Their medication options are limited to phentermine, naltrexone/bupropion combinations, and occasionally topiramate.

What medications does Jorie Weight Loss prescribe? Jorie primarily prescribes phentermine (37.5 mg daily), a stimulant appetite suppressant approved for short-term use. They also use naltrexone/bupropion extended release and occasionally topiramate. All are older weight loss medications with different mechanisms than GLP-1 receptor agonists.

How much weight can you lose at Jorie Weight Loss? Patients who complete the 12-week program typically lose 8% to 12% of body weight during active treatment. At 12 months post-program, average maintained loss is 2% to 4% of baseline weight. About 25% to 35% of patients maintain a 5% or greater loss long-term.

Is Jorie Weight Loss covered by insurance? Most commercial insurance plans do not cover Jorie's program fees, classifying them as wellness services. Some plans cover the initial medical evaluation if coded as obesity counseling. Prescription medications may be covered separately. HSA and FSA funds can typically be used with a letter of medical necessity.

How does Jorie Weight Loss compare to compounded semaglutide? Jorie costs $780 to $940 per month and produces 8% to 12% weight loss over 12 weeks with high regain rates post-program. Compounded semaglutide costs $297 to $399 per month and produces 12% to 15% weight loss at 6 months with sustained results as long as medication continues. Jorie requires weekly in-person visits; semaglutide is telehealth-based.

Can you do Jorie Weight Loss remotely or online? No. Jorie Weight Loss Center requires weekly in-person visits at their Oak Brook clinic location. They do not offer telehealth or remote program options. All weigh-ins, counseling sessions, and medical monitoring happen face-to-face.

What are the side effects of Jorie's weight loss medications? Phentermine commonly causes dry mouth, insomnia, jitteriness, elevated heart rate, and constipation. Naltrexone/bupropion causes nausea (30% of patients initially), headache, and constipation. Topiramate causes cognitive slowing, tingling in extremities, and taste changes. All are generally well-tolerated when properly dosed.

How long do you stay on Jorie's program? The standard program is 12 weeks. Extended options include 26-week and 52-week programs with less frequent visits. Medications like phentermine are FDA-approved for 12 weeks maximum but are sometimes continued off-label for 26 weeks with monitoring. Most patients transition to self-directed maintenance after 12 to 26 weeks.

Does Jorie Weight Loss work long-term? During active participation, Jorie's program produces meaningful weight loss for most completers. Long-term maintenance is challenging. Published data on similar programs shows 25% to 35% of patients maintain 5% or greater weight loss at 12 months post-program. Regain is common once the structure and accountability are removed.

What is the success rate at Jorie Weight Loss Center? Jorie reports that 85% of patients reach their goal weight, but this refers only to program completers and does not account for dropouts (estimated 30% to 40%) or post-program regain. Independent data suggests 60% to 70% complete the program, and 25% to 35% maintain meaningful weight loss 12 months after completion.

Can you switch from Jorie to compounded GLP-1 medication? Yes. Many patients complete Jorie's program to build behavioral skills and habits, then transition to compounded semaglutide or tirzepatide for long-term weight maintenance. There are no contraindications to switching. Most providers recommend a 2 to 4 week washout period after stopping phentermine before starting GLP-1 therapy.

Sources

1. Hendricks EJ et al. Weight loss following phentermine and topiramate extended release: a systematic review. Obesity Reviews. 2012.
2. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
3. Bray GA et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. JAMA. 2004.
4. Unick JL et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes. Obesity Science & Practice. 2019.
5. LeBlanc ES et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. Annals of Internal Medicine. 2016.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
9. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
10. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
11. Gadde KM et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011.
12. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
14. Jensen MD et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Jorie Weight Loss Center is a registered trademark of Jorie Weight Management LLC. Contrave, Ozempic, Wegovy, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.